赤芝酸A | 95311-94-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 赤芝酸A
• 英文名称: lucidenic acid A
• 英文别名: (4R)-4-[(5R,7S,10S,13R,14R,17R)-7-hydroxy-4,4,10,13,14-pentamethyl-3,11,15-trioxo-1,2,5,6,7,12,16,17-octahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid
• CAS: 95311-94-7
• 化学式: C₂₇H₃₈O₆
• 分子量: 458.6
• InChiKey: INIPQDKLXQHEAJ-NCQSLMINSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  33
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  109
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] SMALL MOLECULE COMPOUNDS TO SUPPORT HEALTHY HUMAN AGING<br/>[FR] COMPOSÉS À PETITES MOLÉCULES POUR FAVORISER UN VIEILLISSEMENT HUMAIN SAIN
  申请人：CARDAX PHARMA INC

  公开号：WO2018183353A1

  公开（公告）日：2018-10-04

  Disclosed herein are methods of activating expression of the FOXO3 gene in a subject comprising administering to a subject small molecule compound (such as astaxanthin and/or one or more astaxanthin derivatives), or pharmaceutically acceptable salts thereof, in an amount sufficient to at least partially increase the amount of FoxO3 expressed in the subject.

  本文揭示了一种激活主体中FOXO3基因表达的方法，包括向主体施用小分子化合物（如虾青素和/或一个或多个虾青素衍生物）或其药用可接受盐，以足够数量至少部分增加主体中表达的FoxO3的方法。
• Compound, composition and method for treating and/or ameoliorating kidney disease
  申请人：Trineo Biotechnology Co. Ltd

  公开号：EP2955191A1

  公开（公告）日：2015-12-16

  Disclosed herein are compositions and methods for the treatment or prophylaxis of a subject having or susceptible to a kidney disease. The method includes the step of administering to the subject a compound of formula (I) in a dose of about 1 to 10 mg/Kg to improve the glomerular filtration rate (GFR) of the subject for at least 4 folds as compared to the GFR of the subject before treatment, The method further includes the step of administering to the subject an effective amount of lucidenic acid C (LAC), lucidenic acid N (LAN), lucidenic acid E2 (LAE2), lucidenic acid A (LAA), and lucidenic acid D2 (LAD2).

  本文公开了用于治疗或预防患有或易患肾病的受试者的组合物和方法。该方法包括以下步骤：向受试者施用剂量约为 1 至 10 mg/Kg 的式 (I) 化合物，以改善受试者的肾小球滤过率 (GFR)，与治疗前相比至少提高 4 倍、 该方法进一步包括向受试者施用有效量的葡糖酸C（LAC）、葡糖酸N（LAN）、葡糖酸E2（LAE2）、葡糖酸A（LAA）和葡糖酸D2（LAD2）的步骤。
• JP2005035898A
  申请人：——

  公开号：JP2005035898A

  公开（公告）日：2005-02-10
• COMPOUND, COMPOSITION AND METHOD FOR TREATING AND/OR AMEOLIORATING KIDNEY DISEASE
  申请人：Trineo Biotechnology Co. LTD.

  公开号：US20150353595A1

  公开（公告）日：2015-12-10

  Disclosed herein are compositions and methods for the treatment or prophylaxis of a subject having or susceptible to a kidney disease. The method includes the step of administering to the subject a compound of formula (I) in a dose of about 1 to 10 mg/Kg to improve the glomerular filtration rate (GFR) of the subject for at least 4 folds as compared to the GFR of the subject before treatment, The method further includes the step of administering to the subject an effective amount of lucidenic acid C (LAC), lucidenic acid N (LAN), lucidenic acid E 2 (LAE 2 ), lucidenic acid A (LAA), and lucidenic acid D 2 (LAD 2 ).
• US6726911B1
  申请人：——

  公开号：US6726911B1

  公开（公告）日：2004-04-27